Most Recent Articles about Novo Nordisk A/S
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates http://www.zacks.com/stock/news/356445/pharma-stock-roundup-mrk-buys-imdz-fda-grants-priority-review-to-some-candidates?cid=CS-ZC-FT-356445 Feb 22, 2019 - Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct http://www.zacks.com/stock/news/355654/novo-nordisk-gets-fda-nod-for-haemophilia-drug-esperoct?cid=CS-ZC-FT-355654 Feb 20, 2019 - Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.
Novo Nordisk Has Managed The Turnaround https://seekingalpha.com/article/4240750-novo-nordisk-managed-turnaround?source=feed_sector_healthcare Feb 13, 2019 - Novo Nordisk reported full year results for 2018, and while revenue was still stagnant, earning per share could grow 4%.Due to the launch of new products like Saxenda, Ozempic, and Oral Semaglutide, N

Related Companies

Name Exchange Price Mkt Cap
LLY Eli Lilly and Company NYSE $105.71 $113.53B
ABT Abbott Laboratories NYSE $67.67 $118.71B
SNY Sanofi NYSE $43.75 $109.14B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
Sector: Health Care > Industry: Major Pharmaceuticals